XML 24 R13.htm IDEA: XBRL DOCUMENT v3.26.3
Commitments and Contingencies
9 Months Ended
Sep. 30, 2026
Commitments and Contingencies  
Commitments and Contingencies

Note 7. Commitments and Contingencies

Operating Leases

Sublease and impairment of right-of-use asset

In December 2021, the Company entered into a three-year non-cancellable lease for office space. The lease was extended for an additional five years in March 2024. The lease does not include variable or contingent lease payments. An operating lease asset and liability are recognized based on the present value of the remaining lease payments discounted using the Company’s incremental borrowing rate. Lease expense is recognized on a straight-line basis over the lease term. In the second quarter of 2026, the Company entered into an agreement to sublease the entire premises of its former corporate office at 5 Park Plaza, Irvine, California. The sublease commenced on August 1, 2026 and expires on December 31, 2029. The sublease provides for aggregate fixed lease payments of approximately $0.8 million over the lease term. The Company remains the primary obligor under the master lease and continues to account for it as an operating lease. The Company accounts for the sublease as an operating lease and recognizes sublease income on a straight-line basis over the sublease term. Sublease income is presented separately from lease cost in other income (expense). For the three and nine months ended September 30, 2026, sublease income was $39,000.

In July 2026, the Company vacated the 5 Park Plaza premises and relocated to its new corporate office in Aliso Viejo, California. As a result, the Company evaluated the 5 Park Plaza right-of-use asset as a separate asset group. The carrying amount of the asset group exceeded its undiscounted cash flows, which consist of the expected sublease receipts. The Company therefore recorded a non-cash impairment of the right-of-use asset of $0.2 million, the amount by which its carrying amount exceeded its fair value. The impairment is recorded in operating expenses in the condensed consolidated statements of operations for the three and nine months ended September 30, 2026. The Company also wrote off furniture, fixtures and equipment with a net book value of $64,000 that were left in the premises for the subtenant’s use. The impairment and the loss on disposal totaling $0.3 million are recorded in selling, general and administrative expenses.

In July 2026, the Company entered into a non-cancellable lease for office space in Aliso Viejo, California, which serves as the Company’s corporate headquarters. The lease commenced on August 1, 2026 and expires on October 31, 2029. The lease includes an option to extend the term for three years. The Company is not reasonably certain to exercise the option, so it is excluded from the lease term. Fixed lease payments over the lease term total approximately $0.2 million. The Company’s share of operating expenses, real property taxes, insurance and utilities is a variable lease payment, is expensed as incurred, and is not included in the lease liability.

The lease is classified as an operating lease. At commencement, the Company recognized an operating lease liability of approximately $0.2 million, measured at the Company’s incremental borrowing rate of 13.0%. It also recognized a right-of-use asset of approximately $0.2 million, net of a lease incentive received from the landlord. As of September 30, 2026, the right-of-use asset and operating lease liability for this lease were approximately $0.1 million and $0.2 million, respectively. Operating lease cost for this lease was approximately $10,000 for the three and nine months ended September 30, 2026. 

The following table summarizes supplemental balance sheet information related to both of the operating leases as of September 30, 2026 (in thousands):

​

​

​

​

​

Minimum lease payments by fiscal year

  ​ ​ ​

​

  ​

​

2026 (Remaining)

​

$

80

​

2027

​

 

377

​

2028

​

​

390

​

2029

​

​

390

​

Thereafter

​

​

—

​

Total future minimum lease payments

​

 

1,237

​

Less: Imputed interest

​

 

(109)

​

Present value of lease payments

​

 

1,128

​

Less: Current portion (included in other accrued expenses)

​

 

(307)

​

Noncurrent operating lease liability

​

$

821

​

Operating lease right-of-use asset

​

$

798

​

Remaining lease term in years

​

 

3.2

​

Discount rate

​

 

5.6

%

​

The following table summarizes supplemental disclosures of operating cost and cash flow information related to operating leases for the three and nine months ended September 30, 2026 and 2025 (in thousands).

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

  ​ ​ ​

Nine Months Ended

​

September 30, 

​

September 30, 

​

2026

​

2025

​

2026

​

2025

Cost of operating leases

$

73

​

$

72

​

$

218

​

$

217

Cash paid for operating leases

 

80

​

 

72

​

​

228

​

​

103

Operating lease liabilities arising from obtaining right-of-use assets (non-cash)

​

152

​

​

—

​

​

152

​

​

—

​

The table below summarizes undiscounted sublease payments to be received as of September 30, 2026 (in thousands):

​

​

​

​

Future sublease receipts by fiscal year

  ​ ​ ​

​

  ​

2026 (remaining)

​

$

20

2027

​

​

246

2028

​

​

253

2029

​

​

261

Thereafter

​

​

—

Total

​

$

780

​

Lease Modification

The Company measured the 5 Park Plaza right-of-use asset at fair value on a nonrecurring basis as of July 31, 2026, in connection with the impairment described above. Fair value of $0.7 million was estimated with a discounted cash flow model, an income approach, using the contractual sublease rent over the remaining lease term. The measurement uses significant unobservable inputs and is classified within Level 3 of the fair value hierarchy.

​

​

​

​

​

​

Asset: ROU asset - 5 Park Plaza (July 31, 2026)

​

​

​

​

Valuation technique: Discounted cash flow

​

​

​

​

Fair value

​

$

684

​

Monthly sublease rent

​

$

20.3-22.1

​

Remaining lease term in years

​

 

3.4

​

Discount rate

​

 

8.88

%

​

Daewoong License and Supply Agreement

On December 20, 2019, the Company entered into the Daewoong Agreement, pursuant to which Daewoong agreed to manufacture and supply ABP-450 and grant the Company an exclusive license for therapeutic indications to import, distribute, promote, market, develop, offer for sale and otherwise commercialize and exploit ABP-450 in the United States, the European Union, the United Kingdom, Canada, Australia, Russia, the Commonwealth of Independent States and South Africa (collectively, the “covered territories”).

Daewoong supplies the Company with ABP-450 at an agreed-upon transfer price, with no milestone or royalty payments and no minimum purchase requirements. Daewoong is responsible for all costs related to the manufacturing of ABP-450, including costs related to the operation and upkeep of its manufacturing facility, and the Company is responsible for all costs related to obtaining regulatory approval, including clinical expenses, and commercialization of ABP-450. The Company’s exclusivity is subject to its exercise of commercially reasonable efforts to: (i) achieve all regulatory approvals necessary for ABP-450 to be marketed in the territory for therapeutic indications and (ii) commercialize ABP-450 in the territory for therapeutic indications. During the term of the Daewoong Agreement, the Company cannot purchase, sell or distribute any competing products in a covered territory or sell ABP-450 outside a covered territory.

The initial term of the Daewoong Agreement is from December 20, 2019 to the later of (i) the fifth anniversary of approval from the relevant governmental authority necessary to market and sell ABP-450 or (ii) December 20, 2029, and automatically renews for unlimited additional three-year terms, provided the Daewoong Agreement is not earlier terminated. The Daewoong Agreement will terminate upon written notice by either the Company or Daewoong upon a continuing default that remains uncured within 90 days (or 30 days for a payment default) by the other party, or without notice upon the bankruptcy or insolvency of the Company.

In connection with the Exchange, on January 21, 2026, the Company entered into a Fifth Amendment to the License and Supply Agreement (the “License Agreement Amendment”) with Daewoong, which amended the Daewoong Agreement, by and between the Company and Daewoong, dated December 20, 2019, as amended on July 29, 2022, January 8, 2023, April 24, 2023 and March 19, 2024. Pursuant to the terms of the License Agreement Amendment, the definition of “Notes” reflects the Exchange and the Termination Purchase Right (as defined in the License Agreement Amendment) will terminate and expire upon Daewoong’s sale of 50% of its common stock, including common stock held by its affiliates and common stock that would be issued upon conversion of the New Convertible Note. The Daewoong Agreement, as amended from time to time, also provides that the Daewoong Agreement will terminate if, over any six-month period, (a) the Company ceases to commercialize ABP-450 in certain territories specified in the Daewoong Agreement and (b) the Company ceases to advance any clinical studies of ABP-450 in such territories. Additionally, the Daewoong Agreement also provides that, in the event that the Daewoong Agreement is terminated for the foregoing reasons, Daewoong will have the right to purchase all Know-How (as defined in the Daewoong Agreement) related to ABP-450 for a price of $1.00.

The Company has recorded $0.4 million and $0.4 million as liabilities in accrued expenses and accounts payable on the condensed consolidated balance sheets as of September 30, 2026 and December 31, 2025, respectively, for ABP-450 supplies and analytical testing performed by Daewoong. For the three and nine months ended September 30, 2026 and 2025, the Company recorded de minimis amounts of research and development expenses on the condensed consolidated statement of operations and comprehensive income (loss).

Legal Proceedings

The Company, from time to time, is involved in various litigation matters or regulatory encounters arising in the ordinary course of business that could result in unasserted or asserted claims or litigation. The Company is not subject to any currently pending legal matters or claims that would have a material adverse effect on its accompanying financial position, results of operations or cash flows.

In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. See Note 2 Summary of Significant Accounting Policies for additional information.